Genomic impact of transient low-dose decitabine treatment on primary AMLcells

Blood

Volumn 121, Issue 9, 2013, Pages 1633-1643

  Klco, Jeffery M ^a   Spencer, David H ^a   Lamprecht, Tamara L ^a   Sarkaria, Shawn M ^a   Wylie, Todd ^b   Magrini, Vincent ^b   Hundal, Jasreet ^b   Walker, Jason ^b   Varghese, Nobish ^a   Erdmann Gilmore, Petra ^b   Lichti, Cheryl F ^b,c   Meyer, Matthew R ^b   Townsend, R Reid ^b   Wilson, Richard K ^b   Mardis, Elaine R ^b   Ley, Timothy J ^a,b  

^a Washington University   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE;

ACUTE MYELOID LEUKEMIA CELL; ARTICLE; CANCER CELL; COCULTURE; DNA METHYLATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LOW DRUG DOSE; NUCLEOTIDE SEQUENCE; PRIMARY CELL CULTURE; PRIORITY JOURNAL;

EID: 84876444289     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-459313     Document Type: Article

References (50)

1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
2. Lowenberg B. Strategies in the treatment of acute myeloid leukemia. Haematologica. 2004;89(9): 1029-1032.
3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
4. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918. (Pubitemid 351620111)
5. CashenAF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561.
6. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891. (Pubitemid 47477265)
7. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15(12):3938-3946.
8. Al-Salihi M, Yu M, Burnett DM, Alexander A, Samlowski WE, Fitzpatrick FA. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-Aza-2-deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics. 2011;6(8):1021-1028.
9. Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26(2):244-254.
10. Pinto A, Zagonel V, Attadia V, et al. 5-Aza-2-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4(Suppl 3):28-32. (Pubitemid 20110666)
11. Christman JK. 5-Azacytidine and 5-Aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483-5495. (Pubitemid 34983483)
12. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019-1028.
13. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
14. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-446.
15. Yan P, Frankhouser D, Murphy M, et al. Genomewide methylation profiling in decitabine-Treated patients with acute myeloid leukemia. Blood. 2012;120(12):2466-2474.
16. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
17. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-315.
18. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24(13):1547-1548. (Pubitemid 351911712)
19. Barfield RT, Kilaru V, Smith AK, Conneely KN. CpGassoc: an R function for analysis of DNA methylation microarray data. Bioinformatics. 2012;28(9):1280-1281.
20. Mossman D, Kim KT, Scott RJ. Demethylation by 5-Aza-2-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC cancer. 2010;10:366.
21. Calvanese V, Fernandez AF, Urdinguio RG, et al. A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acids Res. 2012;40(1):116-131.
22. Attema JL, Papathanasiou P, Forsberg EC, Xu J, Smale ST, Weissman IL. Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc Natl Acad Sci U S A. 2007;104(30):12371-12376. (Pubitemid 47206144)
23. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;119(6):1714-1726.
24. Preisler HD, Li B, Chen H, et al. P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia. 2001;15(10):1589-1595. (Pubitemid 32994678)
25. Greco M, D'Alo F, Scardocci A, et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis. 2010;45(3):181-185.
26. Griffiths EA, Gore SD, Hooker CM, et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010;5(7):590-600.
27. Valencia A, Roman-Gomez J, Cervera J, et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia. 2009;23(9):1658-1666.
28. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-Aza-2-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 1997;8(4):358-368. (Pubitemid 27204954)
29. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA- methylationdependent and independent mechanisms. Leukemia. 2005;19(1):103-111. (Pubitemid 40090084)
30. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A. 2009;106(3): 671-678.
31. Bell JT, Pai AA, Pickrell JK, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12(1):R10.
32. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39(4):457-466. (Pubitemid 46514772)
33. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PloS one. 2011;6(3):e17388.
34. Patzke S, Lindeskog M, Munthe E, Aasheim HC. Characterization of a novel human endogenous retrovirus, HERV-H/F, expressed in human leukemia cell lines. Virology. 2002;303(1):164-173. (Pubitemid 36027175)
35. Bell AC, Felsenfeld G. Methylation of a CTCFdependent boundary controls imprinted expression of the Igf2 gene. Nature. 2000;405(6785): 482-485. (Pubitemid 30367427)
36. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosomes Cancer. 2010;49(5):401-411.
37. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997;13(8):335-340. (Pubitemid 27309911)
38. van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ. Establishing long-Term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol. 2007;35(10):1538-1549. (Pubitemid 47419138)
39. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288-295.
40. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011; 6(6):692-702.
41. Harris RA, Wang T, Coarfa C, et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010; 28(10):1097-1105.
42. Yan P, Frankhouser D, Murphy M, et al. Genomewide methylation profiling in decitabine-Treated patients with acute myeloid leukemia. Blood. 2012;120(12):2466-2474.
43. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood. 2010;115(15):3098-3108.
44. Qiu X, Hother C, Ralfkiaer UM, et al. Equitoxic doses of 5-Azacytidine and 5-Aza-2-deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One. 2010;5(9). pii: e12994.
45. Claus R, Pfeifer D, Almstedt M, et al. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res. 2013;37(2):190-196.
46. Si J, Boumber YA, Shu J, et al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res. 2010;70(17):6968-6977.
47. Ley TJ, DeSimone J, Anagnou NP, et al. 5-Azacytidine selectively increases gammaglobin synthesis in a patient with beta thalassemia. N Engl J Med. 1982;307(24):1469-1475. (Pubitemid 13238767)
48. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605-613.
49. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635-1640. (Pubitemid 38268953)
50. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-Azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-2773.